Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Receives $25.71 Consensus PT from Brokerages

Shares of Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) have received an average rating of “Moderate Buy” from the nine ratings firms that are presently covering the company, Marketbeat.com reports. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and seven have given a buy rating to the company. The average twelve-month price target among brokerages that have covered the stock in the last year is $26.1429.

A number of brokerages have commented on DAWN. Zacks Research lowered shares of Day One Biopharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Wednesday. TD Cowen began coverage on Day One Biopharmaceuticals in a research note on Tuesday, January 13th. They issued a “buy” rating and a $34.00 price target on the stock. Wedbush increased their price target on Day One Biopharmaceuticals from $29.00 to $30.00 and gave the company an “outperform” rating in a report on Wednesday. HC Wainwright dropped their price objective on Day One Biopharmaceuticals from $25.00 to $22.00 and set a “buy” rating on the stock in a report on Wednesday. Finally, Needham & Company LLC reduced their target price on Day One Biopharmaceuticals from $18.00 to $17.00 and set a “buy” rating for the company in a research note on Wednesday.

Day One Biopharmaceuticals Stock Down 0.5%

NASDAQ DAWN opened at $10.60 on Friday. Day One Biopharmaceuticals has a fifty-two week low of $5.64 and a fifty-two week high of $13.20. The business has a 50 day moving average price of $10.71 and a two-hundred day moving average price of $8.80. The stock has a market cap of $1.09 billion, a PE ratio of -10.29 and a beta of -1.26.

Day One Biopharmaceuticals (NASDAQ:DAWN) last posted its earnings results on Tuesday, February 24th. The company reported ($0.21) EPS for the quarter, missing analysts’ consensus estimates of ($0.17) by ($0.04). The firm had revenue of $53.72 million for the quarter, compared to analyst estimates of $49.81 million. Day One Biopharmaceuticals had a negative return on equity of 23.43% and a negative net margin of 67.85%. Sell-side analysts anticipate that Day One Biopharmaceuticals will post -0.72 EPS for the current fiscal year.

Insider Transactions at Day One Biopharmaceuticals

In other Day One Biopharmaceuticals news, CFO Charles N. York II sold 6,065 shares of the stock in a transaction on Tuesday, February 17th. The shares were sold at an average price of $11.60, for a total transaction of $70,354.00. Following the transaction, the chief financial officer directly owned 312,025 shares in the company, valued at $3,619,490. This represents a 1.91% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, insider Lauren Merendino sold 5,814 shares of the business’s stock in a transaction dated Tuesday, February 17th. The stock was sold at an average price of $11.60, for a total transaction of $67,442.40. Following the completion of the sale, the insider directly owned 60,157 shares of the company’s stock, valued at $697,821.20. The trade was a 8.81% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 36,461 shares of company stock valued at $422,948 over the last ninety days. 6.20% of the stock is currently owned by corporate insiders.

Institutional Trading of Day One Biopharmaceuticals

Institutional investors and hedge funds have recently bought and sold shares of the company. Invesco Ltd. lifted its holdings in Day One Biopharmaceuticals by 26.5% during the 4th quarter. Invesco Ltd. now owns 123,994 shares of the company’s stock worth $1,156,000 after buying an additional 25,952 shares during the last quarter. Oracle Investment Management Inc. acquired a new stake in shares of Day One Biopharmaceuticals during the 4th quarter valued at approximately $932,000. XTX Topco Ltd raised its position in shares of Day One Biopharmaceuticals by 62.9% during the 4th quarter. XTX Topco Ltd now owns 128,440 shares of the company’s stock valued at $1,197,000 after acquiring an additional 49,592 shares in the last quarter. VARCOV Co. bought a new position in Day One Biopharmaceuticals during the fourth quarter worth $261,000. Finally, Vestal Point Capital LP boosted its holdings in Day One Biopharmaceuticals by 94.4% in the fourth quarter. Vestal Point Capital LP now owns 5,200,000 shares of the company’s stock worth $48,464,000 after purchasing an additional 2,525,000 shares during the period. Institutional investors and hedge funds own 87.95% of the company’s stock.

Key Day One Biopharmaceuticals News

Here are the key news stories impacting Day One Biopharmaceuticals this week:

• Positive Sentiment: Q4 2025 commercial strength and aggressive 2026 guidance — Net product revenues were $52.8M (up ~36% sequentially) and management guided U.S. net product revenues of $225M–$250M for 2026 (midpoint implies ~50% growth over 2025). Company also has several clinical catalysts (Emi‑Le and DAY‑301 readouts in 2026; FIREFLY‑2 possible mid‑2027 readout) that could uplift valuation if positive. Day One Biopharmaceuticals: Commercial Performance With Catalysts Ahead
• Neutral Sentiment: Market sentiment/context — Coverage pieces note improving confidence in broader Nasdaq futures and summarize analyst commentary; these provide background but no single catalyst. DAWN Gaining Confidence In Nasdaq Futures
• Neutral Sentiment: Short‑interest data looks unreliable/insignificant in the latest snapshot (reported 0 shares / data anomalies), so short pressure is not a clear driver today. (No meaningful short‑squeeze signal.)
• Negative Sentiment: Analyst estimate cuts from HC Wainwright — The firm sharply lowered Q1–Q4 2026 and FY2026 EPS forecasts (FY2026 now forecast at -$0.41 vs prior -$0.07) and trimmed out‑year estimates, although it retained a Buy rating and $22 target. The revisions signal weaker near‑term profitability expectations and add downward pressure. HC Wainwright Research Note (DAWN)
• Negative Sentiment: Zacks downgraded DAWN from “strong‑buy” to “hold,” which likely reinforced selling by momentum or quant traders sensitive to rating changes. Zacks Research
• Neutral Sentiment: Analyst roundups (e.g., Benzinga) summarize the mixed views; no single consensus change beyond the above. What Analysts Are Saying About Day One Biopharmaceutical Stock

About Day One Biopharmaceuticals

Day One Biopharmaceuticals, Inc (NASDAQ: DAWN) is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted therapies for oncology. The company employs a precision medicine approach, leveraging biomarker-driven strategies to identify patient populations most likely to respond to its investigational compounds. By concentrating on well-validated molecular drivers of cancer, Day One seeks to deliver first-in-class or best-in-class therapies with the potential for meaningful clinical benefit.

The company’s pipeline includes several small-molecule candidates in various stages of development.